Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib

Hepatocellular carcinoma (HCC) is associated with a poor prognosis and a low chemotherapeutic efficiency except for when sorafenib is administered. The aim of this study was to evaluate the efficacy and adverse events (AEs) of sorafenib therapy in a Chinese population diagnosed with HCC. METHOD: Dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Shou‐Wu, Lee, Teng‐Yu, Yang, Sheng‐Shun, Peng, Yen‐Chun, Yeh, Hong‐Zen, Chang, Chi‐Sen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386742/
https://www.ncbi.nlm.nih.gov/pubmed/30834335
http://dx.doi.org/10.1002/jgh3.12096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386742/
https://www.ncbi.nlm.nih.gov/pubmed/30834335
http://dx.doi.org/10.1002/jgh3.12096

Ejemplares similares